Richard Sposto
YOU?
Author Swipe
View article: Recent evolution of risk analyses in atomic bomb survivor studies: new methods and applications
Recent evolution of risk analyses in atomic bomb survivor studies: new methods and applications Open
Several decades ago a dramatic leap forward occurred in the development and application of statistical methods for modeling radiation risk at the Radiation Effects Research Foundation (RERF). Poisson regression analysis for grouped person-…
View article: A note on potential gains in precision of radiation risk estimates from joint analysis
A note on potential gains in precision of radiation risk estimates from joint analysis Open
View article: Relationship Between Radiation Dose and Markers of Insulin Resistance and Inflammation in Atomic Bomb Survivors
Relationship Between Radiation Dose and Markers of Insulin Resistance and Inflammation in Atomic Bomb Survivors Open
Context In recent studies of childhood cancer survivors, diabetes has been considered a late effect associated with high therapeutic doses of radiation therapy. Our recent study of atomic bomb (A-bomb) survivors also suggested an associati…
View article: The Use of Joint Models in Analysis of Aggregate Endpoints in RERF Cohort Studies
The Use of Joint Models in Analysis of Aggregate Endpoints in RERF Cohort Studies Open
In radiation risk estimation based on the Radiation Effects Research Foundation (RERF) cohort studies, one common analysis is Poisson regression on radiation dose and background and effect modifying variables of an aggregate endpoint such …
View article: Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Open
Supplemental Figure 1 and Figure 2 Legends Supplemental Tables 1-5 Legends
View article: Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC increase tumor engraftment and growth in xenograft model.
View article: Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Open
Comparison of 1 year EFS in two groups defined by a range of ∆CT cut points (left column) and corresponding ROC analysis of the ability of ∆CT values above the cutpoint to predict 1 year EFS (right column), for assays based on …
View article: Data from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium
Data from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium Open
Little is known about neighborhood attributes that may influence opportunities for healthy eating and physical activity in relation to breast cancer mortality. We used data from the California Breast Cancer Survivorship Consortium and the …
View article: Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC and BM-MSC induce activation of STAT3 and ERK1/2 signaling in NB cells
View article: Supplementary Figure 5 from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Supplementary Figure 5 from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas Open
PDF file 92K, Supplemental Fig 5: Expression of PID1 protein in human brain tumors and cell lines
View article: Supplementary Methods, Tables 1 - 2 from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Supplementary Methods, Tables 1 - 2 from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas Open
PDF file - 440K, Supplemental Table 1: Characteristics of the CHLA Medulloblastoma Patients. Supplemental Table 2: Neural and Proneural GBM subgroups have higher PID1 mRNA compared to Classical and Mesenchymal.
View article: Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
A: List of antibodies used in the study B: Clinical characteristics of patients from which CAF-MSC and BM-MSC were isolated.
View article: Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells Open
Supplementary Figure S1 shows that expression of natural cytotoxicity receptors and GD2 on neuroblastoma cells are not affected by TGFbeta1 or galunisertib.
View article: Supplementary Fig. 1-8 from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Supplementary Fig. 1-8 from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Targeting CD105+ Microenvironment cells enhances immunotherpy of Dinutuxmab with aNK cells against neuroblastoma
View article: permission letter from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
permission letter from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Permission letter regarding inclusion of information of CHLA-255 C-Myc over-expression
View article: Figure A2 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Figure A2 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Open
Change in BM and Blood NB5 ÃŽâ€�Ct for patients with progressive disease vs. non-progressive disease. Change in NB5 ÃŽâ€�Ct was assessed between pairs of time points where both NB5 ÃŽâ€�Ct and clinical disease assessments were performed. O…
View article: Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Supplementary Figure Legends from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Open
Supplementary Figure Legends for A1-A3
View article: Data from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Data from <i>PID1</i> (<i>NYGGF4</i>), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas Open
Purpose: We present here the first report of PID1 (Phosphotyrosine Interaction Domain containing 1; NYGGF4) in cancer. PID1 was identified in 2006 as a gene that modulates insulin signaling and mit…
View article: Data from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality
Data from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality Open
Background: Racial/ethnic disparity in breast cancer–specific mortality in the United States is well documented. We examined whether accounting for racial/ethnic differences in the prevalence of clinical, patient, and lifestyle and …
View article: Supplemental Tables 1-4, Supplemental Figure 1 from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality
Supplemental Tables 1-4, Supplemental Figure 1 from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality Open
Supplemental Table 1: Complete CBCSC cohort description, by all baseline model variables (N=12,098). Supplemental Table 2: Project specific sub-cohort description. Supplemental Table 3: Hazard ratio (HR) estimates and 95% confidence interv…
View article: Supplementary Figure Legend, Tables 1 - 2 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy
Supplementary Figure Legend, Tables 1 - 2 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy Open
PDF file - 89K, Supplemental Table 1. List of antibodies used in this study. Supplemental table 2. Cytokines/chemokines excluded from the Luminex� panels.
View article: Data from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Data from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Open
Purpose: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acu…
View article: Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Supplemental Table and Figure Legends from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Open
Supplemental Figure 1 and Figure 2 Legends Supplemental Tables 1-5 Legends
View article: Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Combination of ruxolitinib and trametinib inhibits the growth of subcutaneous NB tumors, cell proliferation and STAT3 and ERK1/2 activation in vivo.
View article: Data from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Data from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Cancer-associated fibroblasts (CAF) have been suggested to originate from mesenchymal stromal cells (MSC), but their relationship with MSCs is not clear. Here, we have isolated from primary human neuroblastoma tumors a population of αFAP- …
View article: Supplemental Table 1 from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium
Supplemental Table 1 from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium Open
Supplemental Table 1. Neighborhood characteristics of the California Breast Cancer Survivorship Consortium by pre-diagnosis BMI.
View article: Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Figure A3 from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis Open
Comparison of 1 year EFS in two groups defined by a range of ∆CT cut points (left column) and corresponding ROC analysis of the ability of ∆CT values above the cutpoint to predict 1 year EFS (right column), for assays based on …
View article: Data from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium
Data from Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium Open
Little is known about neighborhood attributes that may influence opportunities for healthy eating and physical activity in relation to breast cancer mortality. We used data from the California Breast Cancer Survivorship Consortium and the …
View article: Supplementary Tables from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Supplementary Tables from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Supplementary Tables
View article: Supplemental Tables 1-4, Supplemental Figure 1 from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality
Supplemental Tables 1-4, Supplemental Figure 1 from The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality Open
Supplemental Table 1: Complete CBCSC cohort description, by all baseline model variables (N=12,098). Supplemental Table 2: Project specific sub-cohort description. Supplemental Table 3: Hazard ratio (HR) estimates and 95% confidence interv…